Consumers Clamor for CBD as More Novel Uses are Purported

NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Earlier in 2018, the Farm Bill restored industrial hemp to nationwide legal production for the first time since World War II. Removing hemp from the Controlled Substances Act of 1970 (CSA) also helped create a financial domino effect – eventually leading to mass-market retailers CVS Health, Rite Aid, and Walgreens Boots Alliance to carry hemp-CBD brands. Notably, cannabis-based oils have become widely popular because of their potent and immediate effects. In fact, CBD products overall are having a major impact on the global industry because they offer a number of therapeutic benefits without the psychoactive effects of THC. Currently, this segment of the cannabis industry is also gaining prevalence for its potential to treat serious medical conditions such as cancer, multiple sclerosis, Alzheimer's, Parkinson's, depression, and anxiety. And as the U.S. hemp industry matures, it is expected to transition from being a seed, textile, and industrial product importer to a global exporter. And according to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million in 2017. The research also suggests that the industry is expected to grow to USD 1.9 Billion by 2022 and at a CAGR of 14.4% during the 5-year period. U.S. Lithium Corp. (OTC: LITH), Aphria Inc. (NYSE: APHA), CV Sciences, Inc (OTC: CVSI), CannTrust Holdings Inc. (NYSE: CTST), HEXO Corp. (NYSE: HEXO)

The 2018 Farm Bill, however, explicitly preserved the FDA's authority to regulate products containing cannabis or cannabis-derived compounds under the FD&C Act and section 351 of the Public Health Service Act (PHS Act). This leaves a lot of uncertainties regarding which products can be sold legally. According to the FDA, it treats products containing cannabis or cannabis-derived compounds as it does any other FDA-regulated products - meaning they're subject to the same authorities and requirements as FDA-regulated products containing any other substance. This is true regardless of whether the cannabis or cannabis-derived compounds are classified as hemp under the 2018 Farm Bill. And despite the federal regulatory uncertainties, at least 70% of the 2019 U.S. hemp harvest is intended for extract production, with Colorado leading the nation in hemp cultivation and processing land area with over 80,000 acres reported. "The 29 U.S. states reporting licensed hemp cultivation acreage total almost half a million acres in combined cultivation land area, which is a massive increase compared to 2018 figures of a total land area barely over 100,000 acres. While there continues to be uncertainty and a healthy amount of confusion around hemp cultivation for CBD production, it is clear that demand is nonetheless continuing to rise across the U.S.," noted Giadha Aguirre de Carcer, New Frontier Data CEO and Founder. "As states issue more licenses, consumer demand increases, and mass-market retailers such as CVS and Walgreens continue to expand their own product offerings, we expect the FDA may be forced to provide further regulatory clarifications sooner rather than later."

U.S. Lithium Corp. (OTC: LITH) announced earlier last week that, "its Board of Directors and shareholders have approved an amendment to the Articles of Incorporation changing the name of the corporation from U.S. Lithium Corp. to BioELife Corp. The name change will better reflect the Company's new strategic focus on the rapidly growing CBD market. The Company expects this action will become effective within the next 30 days. The Company will also be launching a new website and seek a new trading symbol for its common stock immediately after the name change becomes effective.

'BioELife reflects the Company's new direction into helping improve individual lives through non-addictive remedies for stress and pain relief as well as other medical purposes,' stated Gregory Rotelli, Chairman of the Board and President of LITH. Mr. Rotelli further stated, 'We're positioning our Company as 'Nature's Bio Equivalent' with a 'seed to shelf' philosophy. Our raw materials are sourced directly from our partner farms in America's heartland which grow only the best quality CBD strains for use in all our formulations. Throughout our farming and GMP manufacturing process, our products are made using the purest and most potent ingredients available and are backed by clinical data and independent laboratory testing.'

BioELife currently partners with well-known farmers, certified contract manufacturers and key distributors to produce and distribute exceptional products at the lowest possible cost. Positive testimonials from BioELife clients and patients continue to substantiate the Company's objective to provide products that perform better than any currently on the market and often better than prescription medications.  The Company has already expanded manufacturing and distribution channels in these first few weeks since entering the CBD industry.

About the Company: US Lithium Corp's new strategic direction as BioELife was created by successful pharmaceutical entrepreneurs dedicated to using nature's resources to fight pain and infection while reducing the dependency on opioids and their terrible side effects.  The Company is uniquely positioned to capitalize on the emerging Cannabinoid market that is growing at phenomenal rates and is expected to reach $20 Billion over the next five years. The Company has created a 'seed to shelf' value-added product development and marketing organization with direct contracts for raw materials, scientific formulation, manufacturing, and distribution of medically focused Cannabinoid products. In order to better reflect this new strategic direction, the Company is in the process of changing its name and symbol to BioELife which should be effective within the next thirty days."

For our latest "Buzz on the Street" Show featuring U.S. Lithium Corp. recent corporate news, please head over to: https://www.youtube.com/watch?v=Fh5N0DqJSts

Aphria Inc. (NYSE: APHA) through its subsidiary Aphria Deutschland GmbH announced last april, the launch of the Company's first CBD-based nutraceutical, the first product in its CBD-based cosmetics line for the German market. Featuring CBD derived from hemp, the CannRelief brand of products are being produced in the European Union and distributed by the Company's subsidiary, CC Pharma, which has access to more than 13,000 pharmacies throughout Germany.  "We are excited to introduce our first brand of CBD products for the German nutraceutical and cosmetics market," said Jakob Ripshtein, President of Aphria. "Supported by our extensive distribution network through CC Pharma, CannRelief provides a natural extension to Aphria's growing business opportunities in the German medical cannabis market. We look forward to providing a full range of CannRelief CBD products this year."

CV Sciences, Inc (OTCQB: CVSI), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its brand PlusCBD Oil™, announced that it is the first-ever CBD sponsor of the Farmers Insurance Open. The Farmers Insurance Open is a PGA Golf tournament that took place Thursday, Jan. 23, through Sunday, Jan. 26, at Torrey Pines Golf Course in San Diego, California.  "We are proud to be the official CBD Partner of the Farmers Insurance Open as this serves as another proof point of our commitment to safe, high-quality products," said Joseph Dowling, Chief Executive Officer, CV Sciences.  "We believe both professional and amateur golfers can benefit from PlusCBD™ Oil products and we look forward to increasing our visibility among the golf community through this sponsorship."

CannTrust Holdings Inc. (NYSE: CTST) is a federally regulated licensed producer of medical and recreational cannabis in Canada, and the 2018 Canadian Cannabis Awards "Top Licensed Producer of the Year". CannTrust Holdings Inc. recently announced it has finalized a Letter of Intent with Société québécoise du cannabis to provide Quebec with high-quality cannabis for the recreational market. The LOI will serve as an introduction of CannTrust's recreational brands to the Quebec market beginning with two of the Company's most established strains that will be available through SQDC later this year. "This LOI signifies the first step towards a long and impactful relationship with the SQDC and consumers in Quebec. This is an important milestone as we have secured national distribution across all ten provinces for our adult-use products," said Peter Aceto, Chief Executive Officer, CannTrust. "This will allow us to develop our brand presence in Quebec at a time when consumers are beginning to develop their preferences."

HEXO Corp. (NYSE: HEXO) is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. HEXO Corp. recently announced that it had received licenses from Health Canada for its cannabis Centre of Excellence in Belleville, Ontario, for research, and for the sale of cannabis topicals, extracts, edibles and beverages from its flagship Gatineau campus. While a Processing Licence provides for testing on live plants, fresh and dried plant material, seeds, and oil, a Research and Development Licence significantly expands the scope of work that can be conducted on cannabis and its derivatives. The Company plans to conduct research and development at its Vaughan and Montreal Innovation, Development and Engineering hubs, as well as at its Centre of Excellence in Belleville and in other facilities. "The research licence will allow us to take our innovation work to the next level, with testing on derivative products, including taste testing. Consumers have high expectations for their packaged goods experiences, and cannabis will be no different," said Sebastien St-Louis, Chief Executive Officer and Co-Founder of HEXO Corp. "We are committed to not only ensuring a quality consistent experience but to also guaranteeing that experiences powered by HEXO meet these expectations."

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please NoteFinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has not been compensated for financial news dissemination and PR services by any parties. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.FinancialBuzz.com.

Media Contact:
[email protected]
+1-877-601-1879
www.FinancialBuzz.com

SOURCE FinancialBuzz.com